News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Anavex Life Sciences Corp. (AVXL.OB) Strengthens Alzheimer's Pipeline, Obtains Exclusive Worldwide Rights To Intellectual Property


3/31/2014 9:51:50 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

NEW YORK, March 31, 2014 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (OTCQB:AVXL), a clinical stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's, diseases of the central nervous system (CNS) and various types of cancer, announced today that it has strengthened its Alzheimer's pipeline by obtaining exclusive rights to worldwide patents and patent applications covering methods and compositions for AF710B and other related, preclinical stage compounds from Life Science Research Israel Ltd. (LSRI). LSRI has a proven track record of successfully developing and bringing drugs to market. The licensing of AF710B complements Anavex's existing pipeline in Alzheimer's disease, which is the company's core competency and includes lead clinical candidate ANAVEX PLUS.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES